InsidersTradesSigma
Mesa Laboratories INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the Mesa Laboratories INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mesa Laboratories INC has published 129 insider filings. Market capitalisation: €533m. The latest transaction was filed on 22 June 2022 (Levée d'options). Among the most active insiders: Sullivan John James. All data is accessible without an account.
129
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€7m
34 ops.
Sell Volume
23Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 15,995 of 25,724 companies
44.4
score / 100
Value37
Quality51
FCF yld·
Earn yld1.1%
EV/EBITDA·
ROE2.2%
Gross mgn64%
Net mgn2.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 June 2022
Declarations129 total
1,685 shares0Common StockSEC:0001228924-22-000021:0
392 shares0Common StockSEC:0001228924-22-000018:0
391 shares0Common StockSEC:0001228924-22-000019:0
338 shares0Common StockSEC:0001228924-22-000020:0
30 shares0Common StockSEC:0001228924-22-000013:0
30 shares0Common StockSEC:0001228924-22-000012:0
30 shares0Common StockSEC:0001228924-22-000011:0
30 shares0Common StockSEC:0001228924-22-000010:0
5,192 shares@ US$70.560.064% mcap5.5% of flowCommon StockSEC:0001228924-22-000009:0
5,192 shares@ US$70.560.064% mcap5.5% of flowCommon StockSEC:0001228924-22-000008:0
72 shares@ US$51.850.0006% mcap0.3% of flowCommon StockSEC:0001228924-22-000007:0
1,600 shares@ US$51.850.014% mcap5.9% of flowCommon StockSEC:0001228924-22-000005:0
1,000 shares@ US$70.560.012% mcap1.0% of flowCommon StockSEC:0001228924-22-000004:0
746 shares@ US$70.560.0087% mcap0.7% of flowCommon StockSEC:0001228924-22-000003:0
19,360 shares0Common StockSEC:0001228924-22-000002:0
1,000 shares@ US$97.7811.1% of flowCommon StockSEC:0001228924-22-000001
1,000 shares@ US$97.780.016% mcap11.1% of flowCommon StockSEC:0001228924-22-000001:0
210 shares@ US$142.405.0% of flowCommon StockSEC:0001228924-21-000083
210 shares@ US$142.400.0050% mcap5.0% of flowCommon StockSEC:0001228924-21-000083:0
158 shares@ US$89.701.0% of flowCommon StockSEC:0001228924-21-000082
158 shares@ US$89.700.0024% mcap1.0% of flowCommon StockSEC:0001228924-21-000082:0
1,200 shares@ US$89.708.4% of flowCommon StockSEC:0001228924-21-000081
1,200 shares@ US$89.700.018% mcap8.4% of flowCommon StockSEC:0001228924-21-000081:0
1,000 shares@ US$70.560.012% mcap1.0% of flowCommon StockSEC:0001228924-21-000080:0
1,000 shares@ US$70.561.0% of flowCommon StockSEC:0001228924-21-000080
25 of 129 declarations
About Mesa Laboratories INC
Mesa Laboratories, Inc. (NASDAQ: MLAB) is a United States-listed company traded on the NASDAQ market, with headquarters in Lakewood, Colorado, United States. Founded in 1982, Mesa has built a highly specialized business around critical quality control, monitoring, and measurement solutions used in regulated environments. The company serves customers for whom precision, traceability, and compliance are mission-critical, especially in pharmaceuticals, biotechnology, medical devices, laboratories, and selected industrial applications. From its origins as an instrument and disposable-products manufacturer, Mesa has evolved through a combination of internal development and acquisitions into a portfolio of niche brands with a strong regulatory focus. Today, the company reports four core divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. This structure highlights a strategy centered on technical niches where barriers to entry are meaningful because they depend on regulatory approvals, product reliability, domain expertise, and long-standing customer relationships. Mesa’s product and service portfolio includes biological and chemical indicators for sterilization validation, calibration and metrology solutions, environmental monitoring systems, and tools used in biopharmaceutical development and clinical genomics workflows. The company’s value proposition is framed around protecting patients and workers, improving product integrity, and ensuring the accuracy of critical measurements. In competitive terms, Mesa is not a broad-based volume player; rather, it competes in specialized markets where trust, certification, application expertise, and operational continuity matter more than scale alone. Geographically, Mesa is based in the United States but has an international footprint, with its products and services sold to customers worldwide. Recent corporate highlights include quarterly results showing revenue and profitability progress, debt repayment, and a leadership transition announced in March 2026, when Siddhartha Kadia was named President and CEO. For French-speaking investors, MLAB can be viewed as a quality-oriented healthcare and industrial technology niche company, with exposure to regulatory-driven demand, outsourced quality-control needs, and continued biopharma innovation.
